Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

NextCell Pharma AB: NextCell's cell therapy manufacturing experience highlighted at BIO-Europe 2026

NXTCLPress release2026-11-09 13:00
Discuss

NextCell Pharma AB announces that its Chief Scientific Officer, Dr Lindsay Davies, has been invited to present at BIO-Europe 2026 in Cologne, Germany. Her presentation will address the challenges of taking allogeneic cell therapies from clinical development to commercial production. The conference programme specifically highlights NextCell's experience in developing manufacturing processes for commercial production.

BIO-Europe, taking place on 9-11 November, is Europe's largest partnering conference for the biotechnology and pharmaceutical industries. The event brings together companies and investors from around the world to establish partnerships and explore new business opportunities.

On 10 November, Lindsay Davies will deliver her presentation on the conference's Biomanufacturing Strategy Stage, entitled Future-proofing Manufacturing for Commercialization of Allogeneic Cell Therapies: From Phase II to Global Commercialization. She will address key considerations for commercial production, including scale-up, technology transfer, process validation and regulatory requirements.

The presentation draws on NextCell's experience in manufacturing, process development and quality control gained through the development of its NXTCL cell therapy platform.

Lindsay Davies is also Vice President-Elect for Europe at the International Society for Cell & Gene Therapy (ISCT).

Read more about Lindsay's participation at BIO-Europe 2026: https://informaconnect.com/bioeurope/speakers/lindsay-davies/